Subir material

Suba sus trabajos a SEDICI, para mejorar notoriamente su visibilidad e impacto

 

Mostrar el registro sencillo del ítem

dc.date.accessioned 2021-10-22T14:59:56Z
dc.date.available 2021-10-22T14:59:56Z
dc.date.issued 2012
dc.identifier.uri http://sedici.unlp.edu.ar/handle/10915/127124
dc.description.abstract Reperfusion injury remains one of the major problems in transplantation. Repair from ischaemic acute renal failure (ARF) involves stimulation of tubular epithelial cell proliferation. The aim of this exploratory study was to evaluate the effects of preconditioning donor animals with rapamycin and tacrolimus to prevent ischaemia–reperfusion (I/R) injury. Twelve hours before nephrectomy, the donor animals received immunosuppressive drugs. The animals were divided into four groups, as follows: group 1 control: no treatment; group 2: rapamycin (2 mg/kg); group 3 FK506 (0, 3 mg/kg); and group 4: FK506 (0, 3 mg/kg) plus rapamycin (2 mg/kg). The left kidney was removed and after 3 h of cold ischaemia, the graft was transplanted. Twenty-four hours after transplant, the kidney was recovered for histological analysis and cytokine expression. Preconditioning treatment with rapamycin or tacrolimus significantly reduced blood urea nitrogen and creatinine compared with control [blood urea nitrogen (BUN): P < 0·001 versus control and creatinine: P < 0·001 versus control]. A further decrease was observed when rapamycin was combined with tacrolimus. Acute tubular necrosis was decreased significantly in donors treated with immunosuppressants compared with the control group (P < 0·001 versus control). Moreover, the number of apoptotic nuclei in the control group was higher compared with the treated groups (P < 0·001 versus control). Surprisingly, only rapamycin preconditioning treatment increased anti-apoptotic Bcl2 levels (P < 0·001). Finally, inflammatory cytokines, such as tumour necrosis factor (TNF)-α and interleukin (IL)-6, showed lower levels in the graft of those animals that had been pretreated with rapamycin or tacrolimus. This exploratory study demonstrates that preconditioning donor animals with rapamycin or tacrolimus improves clinical outcomes and reduce necrosis and apoptosis in kidney I/R injury. en
dc.format.extent 169-177 es
dc.language en es
dc.subject Acute tubular necrosis es
dc.subject Apoptosis es
dc.subject Donor preconditioning es
dc.subject Rapamycin es
dc.subject Tacrolimus es
dc.title Preconditioning donor with a combination of tacrolimus and rapamacyn to decrease ischaemia-reperfusion injury in a rat syngenic kidney transplantation model en
dc.type Articulo es
sedici.identifier.other pmid:22132896 es
sedici.identifier.other doi:10.1111/j.1365-2249.2011.04487.x es
sedici.identifier.other pmcid:PMC3248098 es
sedici.identifier.issn 1365-2249 es
sedici.identifier.issn 0009-9104 es
sedici.creator.person Cicora, Federico es
sedici.creator.person Roberti, Javier es
sedici.creator.person Vasquez, Daniela N. es
sedici.creator.person Guerrieri, Diego es
sedici.creator.person Lausada, Natalia Raquel es
sedici.creator.person Cicora, P. es
sedici.creator.person Palti, G. es
sedici.creator.person Chuluyan, E. es
sedici.creator.person González, Pedro Horacio es
sedici.creator.person Stringa, Pablo Luis es
sedici.creator.person Raimondi, Jorge Clemente es
sedici.subject.materias Ciencias Médicas es
sedici.description.fulltext true es
mods.originInfo.place Facultad de Ciencias Médicas es
mods.originInfo.place Comisión de Investigaciones Científicas de la provincia de Buenos Aires es
sedici.subtype Articulo es
sedici.rights.license Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0)
sedici.rights.uri http://creativecommons.org/licenses/by-nc-sa/4.0/
sedici.description.peerReview peer-review es
sedici.relation.journalTitle Clinical and Experimental Immunology es
sedici.relation.journalVolumeAndIssue vol. 167, no. 1 es


Descargar archivos

Este ítem aparece en la(s) siguiente(s) colección(ones)

Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) Excepto donde se diga explícitamente, este item se publica bajo la siguiente licencia Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0)